Epoprostenol

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Epoprostenol
   1. Pharmacist Assessment Report
   2. Epoprostenol: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Epoprostenol: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Epoprostenol, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	8
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
allergic rhinitis
common cold
nasopharyngitis
pharyngitis
pulmonary arterial hypertension
pulmonary hypertension
rhinitis
vasomotor rhinitis

Australia Market Information

Licence	Product	Dosage form	Status
10111E	Veletri	Powder for I.V. infusion 500 micrograms	Valid

Safety Considerations

• Knowledge-graph contraindication signals (not taken from label text): blood coagulation disease and pulmonary oedema.
• Drug Interactions: The interaction screen returned 100 potential interactions in total. The moderate-level ones shown include:
  • Epinephrine
  • Acetylsalicylic acid (aspirin)
  • SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
  • Mannitol
  • Ephedrine (including nasal)
  • Dexfenfluramine and fenfluramine
  • Glycerin
  • Papaverine
  • Sibutramine
• Headache risk: The migraine provocation study (PMID 19614689) is directly relevant to safety in any headache-related use.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---